Axi-cel Demonstrates Durable Responses in Indolent Non-Hodgkin Lymphoma
April 25th 2022Axicabtagene ciloleucel continued to elicit high response rates and durable activity in patients with relapsed/refractory follicular lymphoma and marginal zone lymphoma, according to updated findings from the phase 2 ZUMA-5 trial.
Read More
Sotigalimab Plus Pembrolizumab Elicits Broad Immune Activity in Metastatic Melanoma
April 13th 2022The combination of the CD40 agonist antibody sotigalimab and pembrolizumab demonstrated a favorable safety profile and led to immunologic changes that correlated with clinical response in patients with unresectable stage III or IV metastatic melanoma.
Read More
Niraparib Plus Cabozantinib Shows Early Promise in Advanced Urothelial and Kidney Cancer
February 18th 2022Niraparib in combination with cabozantinib demonstrated a manageable safety profile, with preliminary efficacy observed in heavily pretreated patients with metastatic urothelial carcinoma.
Read More
Regorafenib Plus Pembrolizumab Misses PFS End Point in Microsatellite Stable CRC
January 22nd 2022Pembrolizumab plus regorafenib failed to demonstrate a significant improvement in progression-free survival in pretreated patients with microsatellite stable colorectal cancer (MSSCRC), missing the primary end point of the phase 1/2 trial.
Read More
The addition of daratumumab to lenalidomide, bortezomib, and dexamethasone continued to elicit improved outcomes vs RVd alone in patients with newly diagnosed, transplant-eligible multiple myeloma, according to findings from the extended 2-year follow-up analysis of the phase 2 GRIFFIN trial.
Read More
IPSS, JAK2 Status May Identify Risk for Thrombosis in Primary Myelofibrosis
December 12th 2021The use of the International Prognostic Scoring System score and JAK2 mutation status may identify patients at risk for major arterial and venous thrombosis in primary myelofibrosis, and suggests appropriate anti-thrombotic prophylaxis.
Read More
Higher Oncotype DX Scores Predict for Improved Endocrine Therapy Compliance in ER+ Breast Cancer
December 8th 2021Higher Oncotype DX recurrence scores were associated with prolonged persistence to 5 years of endocrine therapy vs lower Oncotype DX recurrence scores in patients with low-risk, estrogen receptor-positive/progesterone receptor–positive breast cancer, according to findings from a retrospective review.
Read More
CAR T-Cell Therapies Show Promise Across Indolent Lymphomas
September 10th 2021CAR T-cell products targeting CD19 are eliciting clinical activity in patients with indolent non-Hodgkin lymphoma, as seen in the ZUMA-5, SCHOLAR-5, and ELARA trials, but longer follow-up will showcase the true potential of this treatment in this subpopulation.
Read More
Higher Rates of Respiratory Disorders Retrospectively Identified in Polycythemia Vera
September 9th 2021Estimated 4-year mortality rates were greater than 10% in patients with polycythemia vera and vascular complications led to approximately one-third of these deaths, according to a retrospective analysis of the prospective REVEAL trial (NCT02252159) presented during the Society of Hematologic Oncology (SOHO) 2021 Annual Meeting.
Read More
Targeted Therapies, Immunotherapies Slated to Propel T-cell ALL Treatment Paradigm Forward
September 8th 2021The cure rate for patients with T-cell acute lymphoblastic leukemia has improved dramatically over the past few decades, with outcomes becoming comparable to what is observed in those with B-cell acute lymphoblastic leukemia.
Read More
Rituximab Maintenance Improves Time-to-Next Treatment and OS in Patients With Mantle Cell Lymphoma
June 11th 2021Time-to-next treatment and overall survival were improved in a real-world study evaluating patients who received rituximab maintenance after first-line treatment with bendamustine and rituximab or R-CHOP in patients with mantle cell lymphoma.
Read More
Patients with stage III melanoma who progressed following placebo-based treatment in the first part of the phase 3 EORTC 1325/KEYNOTE-054 trial and crossed over to receive pembrolizumab post-recurrence derived a 38.8% overall response rate and a 32% overall 3-year progression-free survival rate.
Read More
Enfortumab Vedotin Showcases Impressive Safety, Efficacy in Cisplatin-Ineligible Urothelial Cancer
February 13th 2021February 12, 2021 - Enfortumab vedotin elicited the highest response rates observed for any regimen examined in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer who received prior PD-1/PD-L1 inhibitors.
Read More
Nab-Paclitaxel Noninferior to Docetaxel in Previously Treated NSCLC
January 29th 2021January 29, 2021 - Nab-paclitaxel proved to be noninferior to docetaxel, having showcased improved progression-free survival, overall survival, and overall response rate in patients with previously treated advanced non–small cell lung cancer.
Read More
Axitinib/Octreotide Combo Fails to Improve PFS in Pancreatic NETs
January 17th 2021January 17, 2021 - Axitinib plus octreotide LAR failed to demonstrate a significant improvement in progression-free survival (PFS) compared with placebo plus octreotide LAR in patients with advanced G1-2 extra-pancreatic neuroendocrine tumors.
Read More
Pevonedistat/Azacitidine Demonstrates Improved Efficacy Vs Single-Agent Azacitidine in MDS
December 8th 2020December 8, 2020 — Pevonedistat in combination with azacitidine improved overall survival and prolonged event-free survival compared with azacitidine monotherapy in patients with higher-risk myelodysplastic syndrome.
Read More
December 6, 2020 — The antibody-drug conjugate belantamab mafodotin continued to showcase efficacy and tolerability in heavily pretreated patients with relapsed/refractory multiple myeloma, inducing durable responses even in those who had previously received 7 or more lines of therapy.
Read More
bb21217 Continues to Showcase Durable Responses in Multiple Myeloma
December 5th 2020December 5, 2020 - The enriched chimeric antigen receptor T-cell therapy bb21217 improved responses and also prolonged duration of response compared with non-enriched CAR T cells in patients with relapsed/refractory multiple myeloma.
Read More
Quad Therapy Induces Deep Responses in Black Patients With Multiple Myeloma
October 16th 2020Data from a subgroup analysis of the phase 2 GRIFFIN study demonstrated that adding daratumumab to lenalidomide, bortezomib, and dexamethasone improved depth of response, stringent complete response, and minimal residual disease negativity, in Black patients with newly diagnosed multiple myeloma.
Read More
Osimertinib/Bevacizumab Combination Fails to Prolong PFS in EGFR T790M+ Lung Cancer
September 20th 2020The combination of osimertinib and bevacizumab did not prolong progression-free survival in patients with advanced adenocarcinoma who had EGFR T790M mutations compared with osimertinib alone
Read More
Robust Data and Multivariate Analyses Support Cabazitaxel as a Standard of Care in mCRPC
May 31st 2020The use of cabazitaxel over abiraterone acetate or enzalutamide may continue as a standard of care in men with metastatic castration-resistant prostate cancer who were previously treated with docetaxel and either of those 2 androgen receptor-targeted agents.
Read More